GHD - Follow-up Survey

In our ongoing efforts to evaluate the impact of CME and to refine future activities, we are asking for a moment of your time to complete a short follow-up survey. The purpose of this survey is to help you reflect on any knowledge gained from the activity and to share with us how you may have changed your approach to assessing and managing your patients. Please complete this follow up survey to be entered into a drawing for a free copy of ESAP 2016.

*
*
*
DefinitelyVery likelyPossiblyUnlikelyNot at allNA
Led to practice improvements
Led to patient benefits

Additional Questions

To help us measure the impact this activity has had on your practice, please answer these brief questions

Case 1. A 15 5/12 y/o female with history of septo-optic dysplasia and hypopituitarism comes to see you for evaluation. She has a confirmed mutation in HesX1. She is on stable thyroid and cortisol replacement. She has been on GH replacement since infancy and had a delayed entry into puberty but now has spontaneous menses regularly. Her height is 63.5” (161.3cm), 50th%, Z score of -0.14, weight is 125# (56 kg). Her growth velocity is <0.5cm/y and her bone age is 14.5yrs. She is visually impaired but goes to regular school and is quite functional. Patient is content with her height and wants to stop GH therapy.

*

Case 2. A 19 6/12 y/o young man with the diagnosis of childhood-onset idiopathic isolated GH deficiency comes to see you for evaluation. He was treated with GH for 7 years and achieved a height of 68.5” (174cm), last GH dose given 2 yrs ago. He is relatively sedentary with a BMI of 22.5kg/m2. He feels well overall, although complaints of easy fatigue. He is in college, majoring in mechanical engineering, occasionally uses alcohol but no drugs. Thyroid, cortisol and testosterone levels are WNL as is his IGF-I for age. DEXA scan shows a lumbar BMD Z score of 0.1SDS, % fat mass 21%. You obtain a GH stimulation test using insulin-induced hypoglycemia. Peak GH to hypoglycemia is 7.8ng/ml.

*